nodes	percent_of_prediction	percent_of_DWPC	metapath
Ethosuximide—CYP2E1—Aminophylline—chronic obstructive pulmonary disease	0.209	0.375	CbGbCtD
Ethosuximide—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0981	0.176	CbGbCtD
Ethosuximide—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0663	0.119	CbGbCtD
Ethosuximide—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0632	0.114	CbGbCtD
Ethosuximide—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0563	0.101	CbGbCtD
Ethosuximide—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0331	0.0594	CbGbCtD
Ethosuximide—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0312	0.0561	CbGbCtD
Ethosuximide—CACNA1G—Nicotine Activity on Chromaffin Cells—CHRNA3—chronic obstructive pulmonary disease	0.0298	0.222	CbGpPWpGaD
Ethosuximide—Myopia—Montelukast—chronic obstructive pulmonary disease	0.0131	0.0425	CcSEcCtD
Ethosuximide—Suicidal ideation—Roflumilast—chronic obstructive pulmonary disease	0.00824	0.0266	CcSEcCtD
Ethosuximide—CYP3A43—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.00492	0.0367	CbGpPWpGaD
Ethosuximide—Gastrointestinal symptom NOS—Salbutamol—chronic obstructive pulmonary disease	0.00471	0.0152	CcSEcCtD
Ethosuximide—CYP3A4—Lidocaine metabolism—CYP1A2—chronic obstructive pulmonary disease	0.0042	0.0314	CbGpPWpGaD
Ethosuximide—CYP3A4—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.00371	0.0277	CbGpPWpGaD
Ethosuximide—CYP3A43—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.00357	0.0267	CbGpPWpGaD
Ethosuximide—Disturbance in attention—Montelukast—chronic obstructive pulmonary disease	0.00331	0.0107	CcSEcCtD
Ethosuximide—Weight decreased—Roflumilast—chronic obstructive pulmonary disease	0.00328	0.0106	CcSEcCtD
Ethosuximide—Aggression—Montelukast—chronic obstructive pulmonary disease	0.00327	0.0106	CcSEcCtD
Ethosuximide—Aggression—Salbutamol—chronic obstructive pulmonary disease	0.00315	0.0102	CcSEcCtD
Ethosuximide—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—chronic obstructive pulmonary disease	0.00304	0.0227	CbGpPWpGaD
Ethosuximide—Connective tissue disorder—Roflumilast—chronic obstructive pulmonary disease	0.00285	0.00921	CcSEcCtD
Ethosuximide—Hirsutism—Prednisolone—chronic obstructive pulmonary disease	0.00273	0.00883	CcSEcCtD
Ethosuximide—Irritability—Aminophylline—chronic obstructive pulmonary disease	0.00267	0.00863	CcSEcCtD
Ethosuximide—Immune system disorder—Roflumilast—chronic obstructive pulmonary disease	0.00262	0.00847	CcSEcCtD
Ethosuximide—Mediastinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.00261	0.00845	CcSEcCtD
Ethosuximide—Abdominal pain upper—Aminophylline—chronic obstructive pulmonary disease	0.00255	0.00825	CcSEcCtD
Ethosuximide—Mental disorder—Roflumilast—chronic obstructive pulmonary disease	0.00254	0.00821	CcSEcCtD
Ethosuximide—Malnutrition—Roflumilast—chronic obstructive pulmonary disease	0.00252	0.00816	CcSEcCtD
Ethosuximide—Hyperkinesia—Montelukast—chronic obstructive pulmonary disease	0.0025	0.00809	CcSEcCtD
Ethosuximide—Sleep disorder—Formoterol—chronic obstructive pulmonary disease	0.00246	0.00795	CcSEcCtD
Ethosuximide—Sleep disorder—Arformoterol—chronic obstructive pulmonary disease	0.00246	0.00795	CcSEcCtD
Ethosuximide—Muscle spasms—Roflumilast—chronic obstructive pulmonary disease	0.00243	0.00785	CcSEcCtD
Ethosuximide—Hyperkinesia—Salbutamol—chronic obstructive pulmonary disease	0.00241	0.0078	CcSEcCtD
Ethosuximide—Sleep disorder—Montelukast—chronic obstructive pulmonary disease	0.00241	0.00778	CcSEcCtD
Ethosuximide—Mental disability—Salbutamol—chronic obstructive pulmonary disease	0.0024	0.00776	CcSEcCtD
Ethosuximide—Euphoric mood—Salbutamol—chronic obstructive pulmonary disease	0.00238	0.00769	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Roflumilast—chronic obstructive pulmonary disease	0.00213	0.0069	CcSEcCtD
Ethosuximide—CYP3A43—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.00209	0.0156	CbGpPWpGaD
Ethosuximide—Haematuria—Aminophylline—chronic obstructive pulmonary disease	0.00205	0.00664	CcSEcCtD
Ethosuximide—CYP3A43—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.00204	0.0153	CbGpPWpGaD
Ethosuximide—Nervous system disorder—Roflumilast—chronic obstructive pulmonary disease	0.00202	0.00653	CcSEcCtD
Ethosuximide—CYP3A43—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.00202	0.0151	CbGpPWpGaD
Ethosuximide—Skin disorder—Roflumilast—chronic obstructive pulmonary disease	0.002	0.00647	CcSEcCtD
Ethosuximide—Irritability—Montelukast—chronic obstructive pulmonary disease	0.00199	0.00643	CcSEcCtD
Ethosuximide—Hirsutism—Prednisone—chronic obstructive pulmonary disease	0.00198	0.00642	CcSEcCtD
Ethosuximide—CYP3A7—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.00198	0.0148	CbGpPWpGaD
Ethosuximide—Irritability—Salbutamol—chronic obstructive pulmonary disease	0.00192	0.0062	CcSEcCtD
Ethosuximide—Cramp muscle—Arformoterol—chronic obstructive pulmonary disease	0.00192	0.00619	CcSEcCtD
Ethosuximide—Cramp muscle—Formoterol—chronic obstructive pulmonary disease	0.00192	0.00619	CcSEcCtD
Ethosuximide—Ataxia—Salbutamol—chronic obstructive pulmonary disease	0.00189	0.00611	CcSEcCtD
Ethosuximide—Cramp muscle—Montelukast—chronic obstructive pulmonary disease	0.00188	0.00607	CcSEcCtD
Ethosuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—HDAC2—chronic obstructive pulmonary disease	0.00184	0.0138	CbGpPWpGaD
Ethosuximide—Abdominal pain upper—Salbutamol—chronic obstructive pulmonary disease	0.00183	0.00593	CcSEcCtD
Ethosuximide—Cramp muscle—Salbutamol—chronic obstructive pulmonary disease	0.00181	0.00585	CcSEcCtD
Ethosuximide—Urinary tract disorder—Tiotropium—chronic obstructive pulmonary disease	0.0018	0.00582	CcSEcCtD
Ethosuximide—Connective tissue disorder—Tiotropium—chronic obstructive pulmonary disease	0.00179	0.00579	CcSEcCtD
Ethosuximide—Decreased appetite—Roflumilast—chronic obstructive pulmonary disease	0.00179	0.00579	CcSEcCtD
Ethosuximide—Urethral disorder—Tiotropium—chronic obstructive pulmonary disease	0.00179	0.00578	CcSEcCtD
Ethosuximide—Eosinophilia—Montelukast—chronic obstructive pulmonary disease	0.00178	0.00576	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.00178	0.00575	CcSEcCtD
Ethosuximide—Fatigue—Roflumilast—chronic obstructive pulmonary disease	0.00178	0.00574	CcSEcCtD
Ethosuximide—CYP2E1—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.00172	0.0128	CbGpPWpGaD
Ethosuximide—Eye disorder—Tiotropium—chronic obstructive pulmonary disease	0.0017	0.00551	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Roflumilast—chronic obstructive pulmonary disease	0.00168	0.00545	CcSEcCtD
Ethosuximide—CYP3A43—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.00166	0.0124	CbGpPWpGaD
Ethosuximide—Immune system disorder—Tiotropium—chronic obstructive pulmonary disease	0.00165	0.00533	CcSEcCtD
Ethosuximide—Suicidal ideation—Prednisone—chronic obstructive pulmonary disease	0.00164	0.00532	CcSEcCtD
Ethosuximide—Mediastinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00164	0.00531	CcSEcCtD
Ethosuximide—Urticaria—Roflumilast—chronic obstructive pulmonary disease	0.00164	0.00529	CcSEcCtD
Ethosuximide—Abdominal pain—Roflumilast—chronic obstructive pulmonary disease	0.00163	0.00527	CcSEcCtD
Ethosuximide—Drowsiness—Montelukast—chronic obstructive pulmonary disease	0.00161	0.00519	CcSEcCtD
Ethosuximide—Mental disorder—Tiotropium—chronic obstructive pulmonary disease	0.0016	0.00517	CcSEcCtD
Ethosuximide—Stevens-Johnson syndrome—Montelukast—chronic obstructive pulmonary disease	0.00159	0.00515	CcSEcCtD
Ethosuximide—Malnutrition—Tiotropium—chronic obstructive pulmonary disease	0.00159	0.00513	CcSEcCtD
Ethosuximide—Hiccups—Prednisolone—chronic obstructive pulmonary disease	0.00159	0.00513	CcSEcCtD
Ethosuximide—Haematuria—Formoterol—chronic obstructive pulmonary disease	0.00156	0.00505	CcSEcCtD
Ethosuximide—Haematuria—Arformoterol—chronic obstructive pulmonary disease	0.00156	0.00505	CcSEcCtD
Ethosuximide—Drowsiness—Salbutamol—chronic obstructive pulmonary disease	0.00155	0.005	CcSEcCtD
Ethosuximide—Agitation—Aminophylline—chronic obstructive pulmonary disease	0.00155	0.005	CcSEcCtD
Ethosuximide—CYP3A4—Aflatoxin B1 metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00154	0.0115	CbGpPWpGaD
Ethosuximide—Hypersensitivity—Roflumilast—chronic obstructive pulmonary disease	0.00152	0.00491	CcSEcCtD
Ethosuximide—CYP3A5—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.00149	0.0111	CbGpPWpGaD
Ethosuximide—CYP3A43—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.00148	0.0111	CbGpPWpGaD
Ethosuximide—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.00148	0.00478	CcSEcCtD
Ethosuximide—Haematuria—Salbutamol—chronic obstructive pulmonary disease	0.00148	0.00477	CcSEcCtD
Ethosuximide—CYP3A43—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.00146	0.0109	CbGpPWpGaD
Ethosuximide—Urinary tract disorder—Arformoterol—chronic obstructive pulmonary disease	0.00145	0.0047	CcSEcCtD
Ethosuximide—Urinary tract disorder—Formoterol—chronic obstructive pulmonary disease	0.00145	0.0047	CcSEcCtD
Ethosuximide—Connective tissue disorder—Arformoterol—chronic obstructive pulmonary disease	0.00145	0.00468	CcSEcCtD
Ethosuximide—Connective tissue disorder—Formoterol—chronic obstructive pulmonary disease	0.00145	0.00468	CcSEcCtD
Ethosuximide—Urethral disorder—Arformoterol—chronic obstructive pulmonary disease	0.00144	0.00466	CcSEcCtD
Ethosuximide—Urethral disorder—Formoterol—chronic obstructive pulmonary disease	0.00144	0.00466	CcSEcCtD
Ethosuximide—CYP3A7—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.00144	0.0108	CbGpPWpGaD
Ethosuximide—CYP2E1—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.00144	0.0107	CbGpPWpGaD
Ethosuximide—CYP3A5—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.00143	0.0107	CbGpPWpGaD
Ethosuximide—Urinary tract disorder—Montelukast—chronic obstructive pulmonary disease	0.00142	0.0046	CcSEcCtD
Ethosuximide—Connective tissue disorder—Montelukast—chronic obstructive pulmonary disease	0.00142	0.00458	CcSEcCtD
Ethosuximide—Urethral disorder—Montelukast—chronic obstructive pulmonary disease	0.00141	0.00457	CcSEcCtD
Ethosuximide—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.00141	0.00456	CcSEcCtD
Ethosuximide—CYP2E1—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00138	0.0103	CbGpPWpGaD
Ethosuximide—CYP3A5—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00138	0.0103	CbGpPWpGaD
Ethosuximide—Urinary tract disorder—Salbutamol—chronic obstructive pulmonary disease	0.00137	0.00444	CcSEcCtD
Ethosuximide—Connective tissue disorder—Salbutamol—chronic obstructive pulmonary disease	0.00137	0.00441	CcSEcCtD
Ethosuximide—Euphoric mood—Prednisolone—chronic obstructive pulmonary disease	0.00136	0.00441	CcSEcCtD
Ethosuximide—Erythema multiforme—Montelukast—chronic obstructive pulmonary disease	0.00136	0.00441	CcSEcCtD
Ethosuximide—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.00136	0.0044	CcSEcCtD
Ethosuximide—Urethral disorder—Salbutamol—chronic obstructive pulmonary disease	0.00136	0.0044	CcSEcCtD
Ethosuximide—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.00135	0.00436	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.00134	0.00434	CcSEcCtD
Ethosuximide—Immune system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00133	0.0043	CcSEcCtD
Ethosuximide—Immune system disorder—Formoterol—chronic obstructive pulmonary disease	0.00133	0.0043	CcSEcCtD
Ethosuximide—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00133	0.00429	CcSEcCtD
Ethosuximide—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00133	0.00429	CcSEcCtD
Ethosuximide—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.00131	0.00423	CcSEcCtD
Ethosuximide—Anorexia—Aminophylline—chronic obstructive pulmonary disease	0.00131	0.00423	CcSEcCtD
Ethosuximide—Immune system disorder—Montelukast—chronic obstructive pulmonary disease	0.0013	0.00421	CcSEcCtD
Ethosuximide—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.0013	0.0042	CcSEcCtD
Ethosuximide—Rash—Roflumilast—chronic obstructive pulmonary disease	0.0013	0.0042	CcSEcCtD
Ethosuximide—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.0013	0.0042	CcSEcCtD
Ethosuximide—Headache—Roflumilast—chronic obstructive pulmonary disease	0.00129	0.00417	CcSEcCtD
Ethosuximide—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.00129	0.00417	CcSEcCtD
Ethosuximide—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.00129	0.00417	CcSEcCtD
Ethosuximide—Malnutrition—Formoterol—chronic obstructive pulmonary disease	0.00128	0.00414	CcSEcCtD
Ethosuximide—Malnutrition—Arformoterol—chronic obstructive pulmonary disease	0.00128	0.00414	CcSEcCtD
Ethosuximide—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.00127	0.00411	CcSEcCtD
Ethosuximide—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.00126	0.00408	CcSEcCtD
Ethosuximide—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.00126	0.00407	CcSEcCtD
Ethosuximide—Immune system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00126	0.00406	CcSEcCtD
Ethosuximide—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00125	0.00405	CcSEcCtD
Ethosuximide—CYP2E1—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.00125	0.00931	CbGpPWpGaD
Ethosuximide—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	0.00123	0.00398	CcSEcCtD
Ethosuximide—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	0.00123	0.00398	CcSEcCtD
Ethosuximide—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.00122	0.00396	CcSEcCtD
Ethosuximide—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.00122	0.00394	CcSEcCtD
Ethosuximide—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.00121	0.00391	CcSEcCtD
Ethosuximide—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	0.00121	0.0039	CcSEcCtD
Ethosuximide—CYP3A43—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.0012	0.00899	CbGpPWpGaD
Ethosuximide—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.00119	0.00386	CcSEcCtD
Ethosuximide—CYP3A4—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.00118	0.00883	CbGpPWpGaD
Ethosuximide—Agitation—Formoterol—chronic obstructive pulmonary disease	0.00118	0.00381	CcSEcCtD
Ethosuximide—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.00118	0.00381	CcSEcCtD
Ethosuximide—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.00116	0.00376	CcSEcCtD
Ethosuximide—Hiccups—Prednisone—chronic obstructive pulmonary disease	0.00115	0.00373	CcSEcCtD
Ethosuximide—Agitation—Montelukast—chronic obstructive pulmonary disease	0.00115	0.00373	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.00112	0.00363	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00112	0.00362	CcSEcCtD
Ethosuximide—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.00111	0.00359	CcSEcCtD
Ethosuximide—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.00109	0.00353	CcSEcCtD
Ethosuximide—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.00109	0.00351	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.00108	0.0035	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.00108	0.0035	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.00106	0.00343	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.00106	0.00343	CcSEcCtD
Ethosuximide—CYP3A43—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.00106	0.00791	CbGpPWpGaD
Ethosuximide—CYP3A43—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.00105	0.00782	CbGpPWpGaD
Ethosuximide—CYP2E1—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.00104	0.00779	CbGpPWpGaD
Ethosuximide—CYP3A5—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.00104	0.00777	CbGpPWpGaD
Ethosuximide—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.00103	0.00333	CcSEcCtD
Ethosuximide—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00103	0.00332	CcSEcCtD
Ethosuximide—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.00103	0.00332	CcSEcCtD
Ethosuximide—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.00102	0.00331	CcSEcCtD
Ethosuximide—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.00102	0.00328	CcSEcCtD
Ethosuximide—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.00102	0.00328	CcSEcCtD
Ethosuximide—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.00101	0.00327	CcSEcCtD
Ethosuximide—Hyperkinesia—Prednisone—chronic obstructive pulmonary disease	0.00101	0.00325	CcSEcCtD
Ethosuximide—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.001	0.00325	CcSEcCtD
Ethosuximide—CYP2E1—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.001	0.00749	CbGpPWpGaD
Ethosuximide—CYP3A5—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.001	0.00748	CbGpPWpGaD
Ethosuximide—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000995	0.00322	CcSEcCtD
Ethosuximide—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.000991	0.0032	CcSEcCtD
Ethosuximide—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000968	0.00313	CcSEcCtD
Ethosuximide—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000959	0.0031	CcSEcCtD
Ethosuximide—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000955	0.00309	CcSEcCtD
Ethosuximide—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000941	0.00304	CcSEcCtD
Ethosuximide—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00094	0.00304	CcSEcCtD
Ethosuximide—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000939	0.00701	CbGpPWpGaD
Ethosuximide—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.00093	0.00301	CcSEcCtD
Ethosuximide—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.00093	0.00301	CcSEcCtD
Ethosuximide—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000916	0.00685	CbGpPWpGaD
Ethosuximide—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000911	0.00294	CcSEcCtD
Ethosuximide—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000909	0.00294	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000903	0.00292	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000903	0.00292	CcSEcCtD
Ethosuximide—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000902	0.00291	CcSEcCtD
Ethosuximide—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000902	0.00291	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000884	0.00286	CcSEcCtD
Ethosuximide—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000883	0.00285	CcSEcCtD
Ethosuximide—CYP3A43—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.00088	0.00657	CbGpPWpGaD
Ethosuximide—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000878	0.00284	CcSEcCtD
Ethosuximide—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000874	0.00282	CcSEcCtD
Ethosuximide—CYP3A43—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000867	0.00648	CbGpPWpGaD
Ethosuximide—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000866	0.0028	CcSEcCtD
Ethosuximide—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000866	0.0028	CcSEcCtD
Ethosuximide—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000861	0.00278	CcSEcCtD
Ethosuximide—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000858	0.00277	CcSEcCtD
Ethosuximide—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000857	0.00277	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000855	0.00276	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000855	0.00276	CcSEcCtD
Ethosuximide—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.000854	0.00276	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000852	0.00276	CcSEcCtD
Ethosuximide—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000851	0.00275	CcSEcCtD
Ethosuximide—CYP3A7—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000841	0.00629	CbGpPWpGaD
Ethosuximide—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000838	0.00271	CcSEcCtD
Ethosuximide—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000831	0.00269	CcSEcCtD
Ethosuximide—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000831	0.00269	CcSEcCtD
Ethosuximide—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000827	0.00267	CcSEcCtD
Ethosuximide—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000827	0.00267	CcSEcCtD
Ethosuximide—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000824	0.00266	CcSEcCtD
Ethosuximide—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000823	0.00615	CbGpPWpGaD
Ethosuximide—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	0.000818	0.00264	CcSEcCtD
Ethosuximide—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000817	0.00264	CcSEcCtD
Ethosuximide—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000816	0.00264	CcSEcCtD
Ethosuximide—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000816	0.00264	CcSEcCtD
Ethosuximide—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000814	0.00263	CcSEcCtD
Ethosuximide—CYP3A7—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000812	0.00607	CbGpPWpGaD
Ethosuximide—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000812	0.00262	CcSEcCtD
Ethosuximide—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.00081	0.00262	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000807	0.00261	CcSEcCtD
Ethosuximide—Irritability—Prednisone—chronic obstructive pulmonary disease	0.000799	0.00258	CcSEcCtD
Ethosuximide—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000796	0.00595	CbGpPWpGaD
Ethosuximide—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000784	0.00254	CcSEcCtD
Ethosuximide—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000781	0.00252	CcSEcCtD
Ethosuximide—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.00077	0.00249	CcSEcCtD
Ethosuximide—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.00077	0.00249	CcSEcCtD
Ethosuximide—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00077	0.00249	CcSEcCtD
Ethosuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—chronic obstructive pulmonary disease	0.000763	0.0057	CbGpPWpGaD
Ethosuximide—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000755	0.00244	CcSEcCtD
Ethosuximide—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.00075	0.00243	CcSEcCtD
Ethosuximide—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.00075	0.00243	CcSEcCtD
Ethosuximide—CYP2E1—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000737	0.00551	CbGpPWpGaD
Ethosuximide—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000735	0.00238	CcSEcCtD
Ethosuximide—CYP3A43—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000734	0.00548	CbGpPWpGaD
Ethosuximide—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000728	0.00235	CcSEcCtD
Ethosuximide—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000724	0.00541	CbGpPWpGaD
Ethosuximide—CYP3A43—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000724	0.0054	CbGpPWpGaD
Ethosuximide—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000716	0.00231	CcSEcCtD
Ethosuximide—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000716	0.00231	CcSEcCtD
Ethosuximide—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000708	0.00229	CcSEcCtD
Ethosuximide—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000701	0.00227	CcSEcCtD
Ethosuximide—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.000694	0.00518	CbGpPWpGaD
Ethosuximide—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000692	0.00224	CcSEcCtD
Ethosuximide—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000692	0.00224	CcSEcCtD
Ethosuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—chronic obstructive pulmonary disease	0.00069	0.00515	CbGpPWpGaD
Ethosuximide—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000677	0.00219	CcSEcCtD
Ethosuximide—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000676	0.00218	CcSEcCtD
Ethosuximide—CYP3A43—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000674	0.00504	CbGpPWpGaD
Ethosuximide—CYP3A7—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000667	0.00498	CbGpPWpGaD
Ethosuximide—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000666	0.00497	CbGpPWpGaD
Ethosuximide—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000665	0.00215	CcSEcCtD
Ethosuximide—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000665	0.00215	CcSEcCtD
Ethosuximide—CYP3A43—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000665	0.00497	CbGpPWpGaD
Ethosuximide—Rash—Formoterol—chronic obstructive pulmonary disease	0.000659	0.00213	CcSEcCtD
Ethosuximide—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000659	0.00213	CcSEcCtD
Ethosuximide—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000659	0.00213	CcSEcCtD
Ethosuximide—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000659	0.00213	CcSEcCtD
Ethosuximide—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000655	0.00212	CcSEcCtD
Ethosuximide—Headache—Formoterol—chronic obstructive pulmonary disease	0.000655	0.00212	CcSEcCtD
Ethosuximide—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000655	0.00212	CcSEcCtD
Ethosuximide—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000653	0.00211	CcSEcCtD
Ethosuximide—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000651	0.00211	CcSEcCtD
Ethosuximide—Rash—Montelukast—chronic obstructive pulmonary disease	0.000646	0.00209	CcSEcCtD
Ethosuximide—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000645	0.00209	CcSEcCtD
Ethosuximide—Headache—Montelukast—chronic obstructive pulmonary disease	0.000642	0.00207	CcSEcCtD
Ethosuximide—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00064	0.00478	CbGpPWpGaD
Ethosuximide—CYP3A43—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000639	0.00477	CbGpPWpGaD
Ethosuximide—CYP3A43—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.00063	0.00471	CbGpPWpGaD
Ethosuximide—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000628	0.00203	CcSEcCtD
Ethosuximide—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000623	0.00201	CcSEcCtD
Ethosuximide—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000622	0.00201	CcSEcCtD
Ethosuximide—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000621	0.00201	CcSEcCtD
Ethosuximide—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000621	0.00201	CcSEcCtD
Ethosuximide—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000619	0.002	CcSEcCtD
Ethosuximide—CYP2E1—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.00061	0.00455	CbGpPWpGaD
Ethosuximide—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000608	0.00197	CcSEcCtD
Ethosuximide—CYP3A5—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000608	0.00454	CbGpPWpGaD
Ethosuximide—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000598	0.00447	CbGpPWpGaD
Ethosuximide—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000596	0.00445	CbGpPWpGaD
Ethosuximide—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000595	0.00444	CbGpPWpGaD
Ethosuximide—CYP3A7—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.00059	0.00441	CbGpPWpGaD
Ethosuximide—CYP2E1—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000588	0.00439	CbGpPWpGaD
Ethosuximide—CYP3A5—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000587	0.00438	CbGpPWpGaD
Ethosuximide—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000587	0.0019	CcSEcCtD
Ethosuximide—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000578	0.00432	CbGpPWpGaD
Ethosuximide—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000569	0.00184	CcSEcCtD
Ethosuximide—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000555	0.00415	CbGpPWpGaD
Ethosuximide—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000541	0.00175	CcSEcCtD
Ethosuximide—CYP2E1—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000536	0.004	CbGpPWpGaD
Ethosuximide—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000526	0.00393	CbGpPWpGaD
Ethosuximide—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000523	0.00169	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—APIP—chronic obstructive pulmonary disease	0.000514	0.00384	CbGpPWpGaD
Ethosuximide—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000508	0.00164	CcSEcCtD
Ethosuximide—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000504	0.00163	CcSEcCtD
Ethosuximide—CACNA1G—NCAM signaling for neurite out-growth—IL6—chronic obstructive pulmonary disease	0.000488	0.00365	CbGpPWpGaD
Ethosuximide—CYP3A7—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000485	0.00362	CbGpPWpGaD
Ethosuximide—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000484	0.00361	CbGpPWpGaD
Ethosuximide—CYP2E1—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000483	0.00361	CbGpPWpGaD
Ethosuximide—CYP3A5—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000482	0.0036	CbGpPWpGaD
Ethosuximide—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000465	0.00348	CbGpPWpGaD
Ethosuximide—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000463	0.0015	CcSEcCtD
Ethosuximide—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.00045	0.00145	CcSEcCtD
Ethosuximide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000436	0.00325	CbGpPWpGaD
Ethosuximide—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000433	0.00323	CbGpPWpGaD
Ethosuximide—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000432	0.00323	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—ADIPOQ—chronic obstructive pulmonary disease	0.000431	0.00322	CbGpPWpGaD
Ethosuximide—CYP2E1—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000427	0.00319	CbGpPWpGaD
Ethosuximide—CYP3A5—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000426	0.00319	CbGpPWpGaD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000426	0.00138	CcSEcCtD
Ethosuximide—CYP3A7—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000426	0.00318	CbGpPWpGaD
Ethosuximide—CYP3A7—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000421	0.00315	CbGpPWpGaD
Ethosuximide—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000417	0.00135	CcSEcCtD
Ethosuximide—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000404	0.0013	CcSEcCtD
Ethosuximide—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.0004	0.00129	CcSEcCtD
Ethosuximide—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000392	0.00127	CcSEcCtD
Ethosuximide—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000375	0.00121	CcSEcCtD
Ethosuximide—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000358	0.00116	CcSEcCtD
Ethosuximide—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000357	0.00115	CcSEcCtD
Ethosuximide—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000357	0.00115	CcSEcCtD
Ethosuximide—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000355	0.00115	CcSEcCtD
Ethosuximide—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000355	0.00115	CcSEcCtD
Ethosuximide—CYP3A7—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000354	0.00265	CbGpPWpGaD
Ethosuximide—CYP2E1—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000351	0.00262	CbGpPWpGaD
Ethosuximide—CYP3A5—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.00035	0.00262	CbGpPWpGaD
Ethosuximide—CYP3A7—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000349	0.00261	CbGpPWpGaD
Ethosuximide—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000342	0.00255	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000341	0.00254	CbGpPWpGaD
Ethosuximide—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000337	0.00109	CcSEcCtD
Ethosuximide—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000336	0.00109	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—GC—chronic obstructive pulmonary disease	0.000331	0.00248	CbGpPWpGaD
Ethosuximide—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000327	0.00106	CcSEcCtD
Ethosuximide—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000325	0.00105	CcSEcCtD
Ethosuximide—CYP2E1—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000309	0.00231	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000308	0.0023	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000308	0.0023	CbGpPWpGaD
Ethosuximide—CYP2E1—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000305	0.00228	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000305	0.00228	CbGpPWpGaD
Ethosuximide—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000303	0.00098	CcSEcCtD
Ethosuximide—CYP3A7—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000295	0.00221	CbGpPWpGaD
Ethosuximide—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000295	0.000954	CcSEcCtD
Ethosuximide—CYP3A7—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000291	0.00218	CbGpPWpGaD
Ethosuximide—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000283	0.00211	CbGpPWpGaD
Ethosuximide—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000282	0.00091	CcSEcCtD
Ethosuximide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000276	0.00207	CbGpPWpGaD
Ethosuximide—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000273	0.00204	CbGpPWpGaD
Ethosuximide—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000272	0.00088	CcSEcCtD
Ethosuximide—CYP3A7—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000272	0.00203	CbGpPWpGaD
Ethosuximide—CYP3A7—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000268	0.002	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—LEP—chronic obstructive pulmonary disease	0.000268	0.002	CbGpPWpGaD
Ethosuximide—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000262	0.000846	CcSEcCtD
Ethosuximide—Rash—Prednisone—chronic obstructive pulmonary disease	0.000259	0.000839	CcSEcCtD
Ethosuximide—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000259	0.000838	CcSEcCtD
Ethosuximide—Headache—Prednisone—chronic obstructive pulmonary disease	0.000258	0.000833	CcSEcCtD
Ethosuximide—CYP3A7—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000257	0.00192	CbGpPWpGaD
Ethosuximide—CYP2E1—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000257	0.00192	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000256	0.00191	CbGpPWpGaD
Ethosuximide—CYP3A7—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000254	0.0019	CbGpPWpGaD
Ethosuximide—CYP2E1—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000253	0.00189	CbGpPWpGaD
Ethosuximide—CYP3A5—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000253	0.00189	CbGpPWpGaD
Ethosuximide—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000248	0.00186	CbGpPWpGaD
Ethosuximide—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000244	0.00079	CcSEcCtD
Ethosuximide—CACNA1G—Axon guidance—MMP9—chronic obstructive pulmonary disease	0.000225	0.00168	CbGpPWpGaD
Ethosuximide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000224	0.00167	CbGpPWpGaD
Ethosuximide—CYP2E1—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000214	0.0016	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000214	0.0016	CbGpPWpGaD
Ethosuximide—CYP2E1—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000211	0.00158	CbGpPWpGaD
Ethosuximide—CYP3A5—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000211	0.00157	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—APIP—chronic obstructive pulmonary disease	0.000207	0.00155	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—VEGFA—chronic obstructive pulmonary disease	0.000202	0.00151	CbGpPWpGaD
Ethosuximide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000201	0.0015	CbGpPWpGaD
Ethosuximide—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000198	0.00148	CbGpPWpGaD
Ethosuximide—CYP2E1—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000197	0.00147	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000196	0.00147	CbGpPWpGaD
Ethosuximide—CYP2E1—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000194	0.00145	CbGpPWpGaD
Ethosuximide—CYP3A5—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000194	0.00145	CbGpPWpGaD
Ethosuximide—CYP2E1—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000186	0.00139	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000186	0.00139	CbGpPWpGaD
Ethosuximide—CYP2E1—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000184	0.00137	CbGpPWpGaD
Ethosuximide—CYP3A5—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000184	0.00137	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—EGFR—chronic obstructive pulmonary disease	0.000182	0.00136	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—GSTT1—chronic obstructive pulmonary disease	0.000181	0.00135	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—GCLC—chronic obstructive pulmonary disease	0.000179	0.00134	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—CTGF—chronic obstructive pulmonary disease	0.000163	0.00122	CbGpPWpGaD
Ethosuximide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000163	0.00122	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—MMP9—chronic obstructive pulmonary disease	0.000161	0.0012	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00015	0.00112	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—APIP—chronic obstructive pulmonary disease	0.00015	0.00112	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—APIP—chronic obstructive pulmonary disease	0.00015	0.00112	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	0.000144	0.00108	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000143	0.00107	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000142	0.00106	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—IL6—chronic obstructive pulmonary disease	0.00014	0.00105	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000137	0.00102	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—GC—chronic obstructive pulmonary disease	0.000133	0.000997	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	0.000133	0.00099	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—EGFR—chronic obstructive pulmonary disease	0.00013	0.000971	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—GSTP1—chronic obstructive pulmonary disease	0.000125	0.000937	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000124	0.000927	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—TNF—chronic obstructive pulmonary disease	0.000124	0.000925	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—HMOX1—chronic obstructive pulmonary disease	0.000124	0.000924	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000119	0.000889	CbGpPWpGaD
Ethosuximide—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000117	0.000877	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—GSTM1—chronic obstructive pulmonary disease	0.000115	0.000861	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000109	0.000816	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—IL6—chronic obstructive pulmonary disease	9.99e-05	0.000746	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	9.94e-05	0.000742	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	9.93e-05	0.000742	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	9.92e-05	0.000741	CbGpPWpGaD
Ethosuximide—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	9.79e-05	0.000732	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—GC—chronic obstructive pulmonary disease	9.67e-05	0.000722	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—GC—chronic obstructive pulmonary disease	9.65e-05	0.000721	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	9.13e-05	0.000682	CbGpPWpGaD
Ethosuximide—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	9e-05	0.000672	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	8.99e-05	0.000671	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	8.97e-05	0.00067	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	8.65e-05	0.000646	CbGpPWpGaD
Ethosuximide—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	8.53e-05	0.000637	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—ALB—chronic obstructive pulmonary disease	7.43e-05	0.000555	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.29e-05	0.000545	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—GCLC—chronic obstructive pulmonary disease	7.21e-05	0.000538	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—NOS3—chronic obstructive pulmonary disease	7.11e-05	0.000531	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	6.96e-05	0.00052	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—CTGF—chronic obstructive pulmonary disease	6.58e-05	0.000491	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.06e-05	0.000453	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.28e-05	0.000394	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.27e-05	0.000394	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—GCLC—chronic obstructive pulmonary disease	5.22e-05	0.00039	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—GCLC—chronic obstructive pulmonary disease	5.21e-05	0.000389	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.05e-05	0.000377	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.98e-05	0.000372	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—CTGF—chronic obstructive pulmonary disease	4.76e-05	0.000356	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—CTGF—chronic obstructive pulmonary disease	4.75e-05	0.000355	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.64e-05	0.000347	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.61e-05	0.000344	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	4.48e-05	0.000335	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.4e-05	0.000329	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.39e-05	0.000328	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.38e-05	0.000327	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	4.17e-05	0.000311	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.66e-05	0.000273	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.65e-05	0.000273	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.61e-05	0.00027	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.6e-05	0.000269	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.36e-05	0.000251	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.36e-05	0.000251	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.19e-05	0.000238	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.18e-05	0.000238	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—ALB—chronic obstructive pulmonary disease	2.99e-05	0.000224	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—NOS3—chronic obstructive pulmonary disease	2.86e-05	0.000214	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.45e-05	0.000183	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	2.42e-05	0.000181	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	2.21e-05	0.000165	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—ALB—chronic obstructive pulmonary disease	2.17e-05	0.000162	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—ALB—chronic obstructive pulmonary disease	2.16e-05	0.000162	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—NOS3—chronic obstructive pulmonary disease	2.07e-05	0.000155	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—NOS3—chronic obstructive pulmonary disease	2.07e-05	0.000155	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.04e-05	0.000152	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.7e-05	0.000127	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.67e-05	0.000125	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.56e-05	0.000117	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.48e-05	0.000111	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	1.01e-05	7.51e-05	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	9.62e-06	7.19e-05	CbGpPWpGaD
